Glioblastoma multiforme-reactive antibodies and methods of use thereof
The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies.
1. An isolated antibody that binds specifically to glioblastoma multiforme (GBM) tumor sphere cells, wherein the anti-GBM antibody comprises an antigen binding site that comprises:
(a) a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO: 2, (ii) CDR-H2 comprising SEQ ID NO: 4, and (iii) CDR-H3 comprising SEQ ID NO: 6, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO: 34, (v) CDR-L2 comprising SEQ ID NO: 36, and (vi) CDR-L3 comprising SEQ ID NO: 38;
(b) a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO: 10, (ii) CDR-H2 comprising SEQ ID NO: 12, and (iii) CDR-H3 comprising SEQ ID NO: 14, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO: 42, (v) CDR-L2 comprising SEQ ID NO: 44, and (vi) CDR-L3 comprising SEQ ID NO: 46;
(c) a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO: 18, (ii) CDR-H2 comprising SEQ ID NO: 20, and (iii) CDR-H3 comprising SEQ ID NO: 22, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO: 50, (v) CDR-L2 comprising SEQ ID NO: 52, and (vi) CDR-L3 comprising SEQ ID NO: 54;
(d) a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO: 26, (ii) CDR-H2 comprising SEQ ID NO: 28, and (iii) CDR-H3 comprising SEQ ID NO: 30, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO: 58, (v) CDR-L2 comprising SEQ ID NO: 60, and (vi) CDR-L3 comprising SEQ ID NO: 62; or
(e) a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO: 67, (ii) CDR-H2 comprising SEQ ID NO: 69, and (iii) CDR-H3 comprising SEQ ID NO: 71, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO: 75, (v) CDR-L2 comprising SEQ ID NO: 77, and (vi) CDR-L3 comprising SEQ ID NO: 79.
2. The anti-GBM antibody of claim 1 , wherein the antigen binding site comprises the heavy chain variable region of SEQ ID NO: 8, and the light chain variable region of SEQ ID NO: 40.
3. The anti-GBM antibody of claim 1 , wherein the antigen binding site comprises the heavy chain variable region of SEQ ID NO: 16, and the light chain variable region of SEQ ID NO: 48.
4. The anti-GBM antibody of claim 1 , wherein the antigen binding site comprises the heavy chain variable region of SEQ ID NO: 24, and the light chain variable region of SEQ ID NO: 56.
5. The anti-GBM antibody of claim 1 , wherein the antigen binding site comprises the heavy chain variable region of SEQ ID NO: 32, and the light chain variable region of SEQ ID NO: 64.
6. The anti-GBM antibody of claim 1 , wherein the antigen binding site comprises the heavy chain variable region of SEQ ID NO: 73, and the light chain variable region of SEQ ID NO: 81.
7. An isolated anti-GBM antibody that competes for binding to glioblastoma multiforme (GBM) tumor sphere cells with the anti-GBM antibody of claim 1 .
8. The anti-GBM antibody of claim 1 , wherein the antibody inhibits proliferation of GBM tumor sphere cells.
9. The anti-GBM antibody of claim 1 , wherein the antibody is an antibody fragment.
10. The anti-GBM antibody of claim 9 , wherein the fragment is an Fab, F(ab′) 2 , Fv or Sfv fragment.
11. The anti-GBM antibody of claim 1 , wherein the antibody is a full-length human immunoglobulin g (IgG) antibody.
12. The anti-GBM antibody of claim 1 , wherein the antibody is coupled to one of the group consisting of a detectable marker, and a chemotherapeutic agent.
13. The anti-GBM antibody of claim 12 , wherein the antibody is coupled to a detectable marker selected from the group consisting of a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound, and a chemiluminescent compound.
14. The anti-GBM antibody of claim 13 , wherein the radioisotope comprises one of the group consisting of 212 Bi, 131 I, 131 In, 90 Y, 186 Re, 211 At, 125 I, 188 Re, 153 Sm, 213 Bi, 32 P, and 177 Lu.
15. The anti-GBM antibody of claim 12 , wherein the antibody is coupled to a chemotherapeutic agent.
16. A method for characterizing a biopsy sample from a patient, comprising:
a) contacting the sample with the anti-GBM antibody of claim 1 ;
b) detecting the binding of the anti-GBM antibody to cells of the sample; and
c) characterizing the sample as containing cells expressing an antigen bound by the anti-GBM antibody when binding is detected.
17. The method of claim 16 , wherein the biopsy sample is from a brain tumor.
18. A method for treating a cancer patient having tumor cells that express an antigen bound by an anti-GBM antibody, comprising:
A) providing a composition comprising the anti-GBM antibody comprising an antigen binding site that comprises
(a) a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO: 2, (ii) CDR-H2 comprising SEQ ID NO: 4, and (iii) CDR-H3 comprising SEQ ID NO: 6, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO: 34, (v) CDR-L2 comprising SEQ ID NO: 36, and (vi) CDR-L3 comprising SEQ ID NO: 38;
(b) a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO: 10, (ii) CDR-H2 comprising SEQ ID NO: 12, and (iii) CDR-H3 comprising SEQ ID NO: 14, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO: 42, (v) CDR-L2 comprising SEQ ID NO: 44, and (vi) CDR-L3 comprising SEQ ID NO: 46;
(c) a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO: 18, (ii) CDR-H2 comprising SEQ ID NO: 20, and (iii) CDR-H3 comprising SEQ ID NO: 22, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO: 50, (v) CDR-L2 comprising SEQ ID NO: 52, and (vi) CDR-L3 comprising SEQ ID NO: 54;
(d) a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO: 26, (ii) CDR-H2 comprising SEQ ID NO: 28, and (iii) CDR-H3 comprising SEQ ID NO: 30, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO: 58, (v) CDR-L2 comprising SEQ ID NO: 60, and (vi) CDR-L3 comprising SEQ ID NO: 62; or
(e) a heavy chain comprising (i) complementarity determining region (CDR)-H1 comprising SEQ ID NO: 67, (ii) CDR-H2 comprising SEQ ID NO: 69, and (iii) CDR-H3 comprising SEQ ID NO: 71, and a light chain comprising (iv) CDR-L1 comprising SEQ ID NO: 75, (v) CDR-L2 comprising SEQ ID NO: 77, and (vi) CDR-L3 comprising SEQ ID NO: 79; and
B) administering to the patient the composition in an amount effective to inhibit proliferation of the tumor cells of the patient.
19. The method of claim 18 , wherein the tumor cells are glioblastoma multiforme (GBM) tumor cells.
20. The method of claim 18 , wherein the composition is administered intravenously or intracranially.
21. The method of claim 18 , further comprising administering an effective amount of an additional chemotherapeutic agent to the patient.
22. The method of claim 18 , further comprising one or both of surgically resecting the tumor cells and administering radiation therapy.